Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on the Efficacy and Safety of Donafenib Combined With Hepatic Artery Infusion Chemotherapy and Sintilimab as the First-line Treatment for Unresectable Hepatocellular Carcinoma - the DoHAICs Study Expansion Phase

NCT07584018 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT07584018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07584018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on the Efficacy and Safety of Donafenib Combined With Hepatic Artery Infusion Chemotherapy and Sintilimab as the First-line Treatment for Unresectable Hepatocellular Carcinoma - the DoHAICs Study Expansion Phase
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 20, 2026
Completion date
June 1, 2027
Enrollment
90 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hcc - hepatocellular carcinoma